SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-037814
Filing Date
2020-08-06
Accepted
2020-08-06 16:36:52
Documents
70
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q eidx-10q_20200630.htm   iXBRL 10-Q 2406514
2 EX-31 eidx-ex31_6.htm EX-31 19275
3 EX-32 eidx-ex32_7.htm EX-32 9961
  Complete submission text file 0001564590-20-037814.txt   8696339

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eidx-20200630.xsd EX-101.SCH 57755
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE eidx-20200630_cal.xml EX-101.CAL 41520
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE eidx-20200630_def.xml EX-101.DEF 207502
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE eidx-20200630_lab.xml EX-101.LAB 446291
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eidx-20200630_pre.xml EX-101.PRE 345778
9 EXTRACTED XBRL INSTANCE DOCUMENT eidx-10q_20200630_htm.xml XML 1683736
Mailing Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104
Business Address 101 MONTGOMERY STREET, SUITE 2550 SAN FRANCISCO CA 94104 650-391-9740
Eidos Therapeutics, Inc. (Filer) CIK: 0001731831 (see all company filings)

IRS No.: 463733671 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38533 | Film No.: 201082302
SIC: 2834 Pharmaceutical Preparations